Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

In particular, the organisation is unhappy with Kennedy's repeated assertions that Alzheimer's research has been dedicated to ...

SNY inks an agreement to acquire VIGL and its pipeline candidate VG-3927, which is being developed to treat Alzheimer's ...

Eli Lilly (NYSE:LLY) has received regulatory approval to market its Alzheimer’s therapy Kisunla (donanemab) in Australia, ...

According to the latest study from BCC Research, "Neurology Market: A BCC Research Overview" is estimated to increase from ...

The test will initially be available at about 50 American research institutes and hospitals that specialise in Alzheimer’s ...

China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most ...

The first blood test to help diagnose Alzheimer's disease will be available from late June in the US following regulatory ...

The test potentially makes it easier to find and treat patients with the memory-robbing disease. Read more at ...

A dementia-focused transatlantic venture capital initiative has secured $269 million in commitments for its second fund. | A ...